Arvinas, Inc. (ARVN) Earnings Call Transcript
May 12, 2026
Earnings Call Speaker Segments
Hello, everyone, and thanks for being with us this morning. We put out a press release earlier today covering the financial results for our first quarter of 2026, and you can find it in the Investor and Media section on arvinas.com. On the line with us today are Randy Teel, who serves as our President and CEO; Noah Berkowitz, our Chief Medical Officer; Angela Cacase, our Chief Scientific Officer; and Andrew Saik, our Chief Financial Officer. Before getting started, I want to note that statements made during today's discussion include forward-looking statements involving risks, uncertainties and assumptions. Those risks and uncertainties are described in today's press release as well as in the company's recent filings with the Securities and Exchange Commission, and I encourage you to read them. What actually happens could differ materially from what we discuss on today's call. A replay of this call, along with today's press release and a refreshed corporate deck, will be posted in the Investor and Media section of our website; and with that, I'll hand things over to Randy Teel. Randy?
Thanks, Jeff, and I appreciate everyone being here today. Ever since I took on the CEO position earlier this year, my regard for how strong the Arvinas platform is, the skill and execution ability our team brings, and the depth and distinctiveness of our pipeline has done nothing but increase. Being the initial PROTAC degrader company, we feel we have established translational know-how in protein degradation that no one else matches. My view is that we are set up extremely well for a 2026 that is both highly productive and value-generating. A number of months back, following our submission of the new drug application for vepdegestrant, we made public our plan to find a third party capable of maximizing the commercial opportunity for it. Throughout this period, our confidence has not wavered that vepdegestrant could turn into a meaningful treatment choice for people living with metastatic breast cancer. That confidence of ours was confirmed when the FDA recently approved vepdeg, which is now called VEPPANU. And then yesterday afternoon, we were happy to share that together with Pfizer, we have signed a global licensing agreement with Rigel Pharmaceuticals covering commercialization, development and manufacturing of VEPPANU. Let me start with the FDA's approval of VEPPANU for treating ESR1-mutant, ER+/HER2- advanced breast cancer. For patients and physicians alike, this marks a significant milestone, and it shows what targeted protein degradation can do in treating disease. Second-line treatment choices for these patients have been scarce; and as the lead investigator in our Phase 3 trial set, the approval of VEPPANU delivers renewed hope to patients in need of additional options. VEPPANU's approval represented the very first approval ever of a heterobifunctional PROTAC degrader; within our industry, not many biotechs manage to successfully take a molecule all the way from discovery through approval. Even fewer companies end up on the extremely short list of firms, whether large or small, that have ever been first to take a new therapeutic modality from inception to approval. In our view, this accomplishment provides full validation of our innovative targeted degrader platform, which Arvinas pioneered over 10 years ago. It additionally bolsters our confidence in the breadth and versatility of our exciting Phase 1 pipeline spanning oncology, neurodegenerative disorders and neuromuscular diseases. My gratitude goes out deeply to the team that has labored tirelessly on VEPPANU, holding the unwavering belief that it can deliver renewed hope to patients who need new treatment options. We are dedicated to ensuring VEPPANU becomes available for patients as soon as possible. Rigel possesses a fully established oncology sales team along with the infrastructure required to make sure VEPPANU is available soon. They are dedicated to unlocking VEPPANU's full value, and our confidence is high that they are the right partner to deliver this important treatment to the patients who need it. Simultaneously, this agreement permits Arvinas to put resources into the next wave of innovation throughout our pipeline while keeping a strong and disciplined approach to capital allocation. In fact, that was the reasoning behind pursuing a new partner for VEPPANU, so that patients could receive VEPPANU while Arvinas could devote itself to our next generation of degraders. It's a privilege to head up a company that is pushing forward a portfolio of degraders which stands out within the industry. With patient genetics as our compass and by pinpointing the key drivers behind disease, we make a point of choosing targets where breaking down proteins can produce a transformative effect. Up to now, over 2,000 patients along with healthy volunteers have received doses through our PROTAC technology, and our people have achieved outstanding results in moving promising compounds out of preclinical work and into clinical programs. Looking forward, there's no ambiguity about what we're aiming for. It isn't merely about moving molecules into the clinic. Our focus is unrelenting when it comes to building differentiated therapies that set a higher standard for patients in safety, tolerability and efficacy. Incremental gains aren't what we're after; instead, we're striving to fundamentally reshape what is possible for patients and clinicians. And we're pursuing this from a position of strength. Thanks to a solid balance sheet and a team that is deeply dedicated, we're well situated to create long-term value for patients, their families and our shareholders; we find ourselves in the promising situation of running 4 Phase 1 clinical programs concurrently, with the capital required to hit key inflection points across each of those programs, which will shape where we direct our investment and how we continue developing them. At this point I'll hand things over to Noah and the team. Noah?
Thanks, Randy. Morning, everybody, and I appreciate you being with us today. At Arvinas, we've got a thrilling year in front of us, starting with the Phase 1 results for our lead candidate, ARV-102, which we shared recently at AD/PD. Those findings mark a significant step forward and strongly confirm the way we're approaching neurodegenerative diseases. ARV-102 is an oral PROTAC built to get past the blood-brain barrier and to degrade LRRK2 in a potent, selective way — LRRK2 being a multi-domain protein that governs neuroinflammation along with lysosomal and synaptic function. Higher LRRK2 levels play a role in conditions such as progressive supranuclear palsy, or PSP, and Parkinson's disease. Because it degrades the entire LRRK2 protein complex — its scaffolding, GTPase and kinase functions included — ARV-102 hits several disease-relevant pathways, unlike kinase inhibitors that go after just one function; we've demonstrated that ARV-102 gets into the CNS, delivers dose-dependent decreases of LRRK2 and cerebrospinal fluid, and influences downstream proteins tied to the disease. At AD/PD, Phase 1 results from Parkinson's disease patients showed roughly 50% or more decreases in CSF LRRK2 by day 14 at all dose levels, maintained through day 28, which lines up with our aim of normalizing the approximately twofold LRRK2 elevation seen in Parkinson's disease. Notably, degrading LRRK2 produced dose-dependent decreases in neuroinflammation and lysosomal stress biomarkers, among them CD68 and GPNMB. As far as we know, biomarker modulation at this level hasn't been seen with LRRK2 inhibitors. Through 28 days of dosing, ARV-102 was also generally well tolerated, with no serious adverse events. These results back our move into PSP, which is our near-term clinical priority. PSP is a fast-progressing tauopathy caused by 4-hour tau accumulation, with typical survival of 5 to 7 years and no disease-modifying treatments. Among PSP patients, higher LRRK2 expression is tied to faster and clinically meaningful progression within one year. In preclinical work, we've shown ARV-102 affects neuroinflammation, boosts endolysosomal function and, most crucially, lowers tau pathology across several relevant disease models, which matches our clinical findings of better endolysosomal function and less neuroinflammation. All of this information reinforces our conviction that breaking down LRRK2 could offer a distinct, disease-altering approach to treating PSP — a terrible and deadly condition that currently has no treatment options, impacting 25,000 people across the United States. I also want to share an update regarding the timing for kicking off our Phase 1b clinical study of ARV-102 in patients with progressive supranuclear palsy. We submitted an IND at the start of this year, with plans to get the trial going in the U.S. sometime in the first half of the year. Following the 30-day review window, the FDA requested the final results from our chronic toxicity studies conducted in nonhuman primates prior to granting permission for the Phase 1b to commence in the U.S. among PSP patients. That requirement means the study we had planned is currently under a clinical hold, and it cannot begin until we provide the requested data. No patients in the U.S. have received a dose. We expect to have those data around the middle of 2026, and we anticipate the U.S. trial will launch before the end of 2026. We do not believe this will affect our plans for studies in the EU. So our timeline for kicking off the Phase 2 trial has not changed, and we plan to conduct it as a global study. Now let's turn to oncology, beginning with ARV-806, our KRAS G12D degrader. KRAS G12D is a well-known cancer-driving mutation that leads to bad outcomes and makes standard treatments stop working in several kinds of tumors, including pancreatic, colorectal, and non-small cell lung cancers. ARV-806 was designed to strongly and specifically eliminate both the ON and OFF versions of KRAS G12D, and that's an important distinguishing feature for a hard-to-treat solid tumor target. What gives us confidence in ARV-806 comes from strong preclinical data, which revealed about 25 to 40 times more potency compared to KRAS G12D inhibitors and degraders that are in clinical stages; those results also showed degradation lasting more than 90% over 7 days after just one dose, with responses in pancreatic, colorectal, and lung cancer models. During our last quarterly update, we mentioned that patient accrual for the dose escalation portion of the ongoing Phase 1 study testing once-weekly dosing wrapped up much faster than anticipated. That swift uptake signals to us that investigators are highly engaged and that significant unmet need exists among those with KRAS-driven cancers. The early findings we plan to present before the year is out, we believe, will serve as an initial demonstration of what ARB-806 could offer as a distinct and clinically valuable therapeutic choice for individuals battling KRAS-driven cancers. And lastly, a word on ARD-393, which is our PROTAC BCL6 degrader. Enrollment and treatment continue to move forward in the Phase 1 dose escalation study of this agent as a monotherapy for people with B-cell and T-cell lymphomas who have already undergone several lines of treatment. The early responses we've seen in both groups are really encouraging to us—especially those occurring at doses lower than the level we'd anticipated would be necessary for efficacy. On top of that, we've seen strong degradation of BCL6, which stands out as a significant observation since this protein gets resynthesized quickly. Later in the year, we're eager to provide further clinical data from the Phase 1 monotherapy study we're currently running in relapsed or refractory non-Hodgkin's lymphoma patients. While continuing to enroll people into that monotherapy group, we've also launched a trial testing a combination with glofitamab in diffuse large B-cell lymphoma patients—a key next move as we aim to broaden what ARV-393 might be able to do. With that said, I'll hand things over now to Angela. Angela?
Thank you, Noah, and good morning to all of you. I'd like to start with the patients who have spinal and bulbar muscular atrophy, which people also call SBMA or Kennedy's disease. These individuals suffer from a progressive neuromuscular condition that gradually takes away their muscle strength and endurance; this is an X-linked disorder brought on by an expansion of CAG repeats within the androgen receptor gene, resulting in accumulation of a toxic protein form — polyglutamine expanded AR, or polyQ-AR, in skeletal muscle; that buildup interferes with typical muscle function, causes atrophy and, as time passes, has a major effect on quality of life. Put differently, polyQ-AR represents the root cause of this illness, and right now no approved disease-modifying treatments exist for these patients. With ARV-027, we designed a PROTAC degrader with the specific goal of clearing the toxic polyQ-AR protein out of muscle cells. By eliminating the driver of pathology instead of merely managing symptoms, our aim is to preserve muscle function and change how the disease progresses. We have now enrolled the first 3 cohorts in our Phase 1 single-ascending dose trial in healthy volunteers, which marks an important step forward for the program. Because of our deep experience with AR degraders, we are confident in our ability to turn this approach into clinical benefit. Earlier this year, at the Kennedy's Disease Association Conference, we presented preclinical data from an aggressive SBMA mouse model demonstrating that our oral ARV-027, by degrading polyQ-AR in muscle, produced meaningful functional improvements and prolonged survival. As a reminder, we have an excellent track record in developing AR degraders. Our first clinical candidate was an AR degrader, and luxdegalutamide, which we out-licensed to Novartis in 2024, is moving through multiple Phase 2 trials in hormone-sensitive and castration-resistant prostate cancer. We are enthusiastic about ARV-027's potential to become the first disease-modifying therapy for patients with SBMA. Let me now shift to the discovery pipeline as we get closer to the clinic. First, ARV-6723, our oral immuno-oncology PROTAC degrader for solid tumors. The target here is HPK1, which serves as a brake on the immune system. It blunts T-cell signaling and suppresses both innate and adaptive antitumor responses. What makes HPK1 especially difficult as a target is that it operates in 2 ways: not only via its kinase activity, but also as a signaling scaffold. So inhibition by itself cannot fully shut it down — degradation can. And that is precisely what we observe with ARV-6723: deep, sustained elimination of the protein and both of its functions. In preclinical models, the data are highly compelling. We observe strong single-agent antitumor activity across multiple tumor types, including both high and low immunogenic settings. In fact, ARV-6723 demonstrated greater tumor growth inhibition, beating both an HPK1 inhibitor and anti-PD-1. Even more importantly, in 7 checkpoint-resistant models, ARV-6723 displayed activity as a single agent while the inhibitor and anti-PD-1 showed none. And mechanistically, this goes beyond T-cells. We are seeing reversal of the immunosuppressive tumor microenvironment, as we just presented at the American Association for Cancer Research Conference. ARV-6723 produces a significant effect on the myeloid compartment, something that standard checkpoint therapies generally do not accomplish. So to zoom out, we think this program could genuinely transform the treatment paradigm within the immuno-oncology space, and we remain on schedule to begin clinical testing later this year. Last, let me discuss our oral pan-KRAS PROTAC program. Three main points define it. First, we observe broad KRAS degradation across a range of alterations, such as wild-type amplified KRAS, with selectivity over other RAS isoforms. Importantly, it is active in both the ON and the OFF signaling states. Second, from a biological standpoint, by degrading the protein and eliminating the oncoprotein instead of merely inhibiting it, we observe more potent anti-proliferative and pro-apoptotic effects, as well as greater tumor growth inhibition. Third, in preclinical models, this strategy demonstrates improved activity, particularly when combined with anti-PD-1 relative to the investigational pan-RAS (ON) inhibitor. That leaves us confident in a differentiated pan-KRAS degradation approach that additionally complements our KRAS G12D program. We will provide further updates later this year. With that, I'll hand the call to Andrew to go over our quarterly financial results. Andrew?
Thank you, Angela, and good morning to all of you. It's my pleasure to walk through the financial highlights covering the first quarter and the full year that concluded on March 31, 2026. Just a reminder that comprehensive financial results for Q1 can be found in the press release we put out earlier today. Echoing what the team has expressed, there's a great deal ahead of us in the remainder of this year, and we're happy about our solid financial footing, which enables us to keep moving our pipeline forward into the latter half of 2028. As of the close of Q1, our balance sheet showed $614.9 million across cash, cash equivalents, and marketable securities, down from $685.4 million at the close of 2025. Given our robust balance sheet and our emphasis on the early-stage pipeline, we're in a strong position to keep developing our encouraging oncology and neurology programs. Now to the Q1 2026 financial highlights. Revenue for the 3 months that ended March 31, 2026, came to $15.6 million, versus $188.8 million for the equivalent period in 2025. That $173.2 million drop stemmed from reduced revenue recognized under the vepdegestrant collaborative agreement with Pfizer, which was driven by adjustments to estimated remaining program costs. General and administrative expenses totaled $19.1 million in Q1, compared with $26.6 million for the same period of 2025. The $7.5 million decline was mainly attributable to a $5.3 million reduction in professional fees. Research and development expenses reached $60.3 million in the first quarter, versus $90.8 million for the same period of 2025. That $30.5 million decrease was primarily the result of a $15.6 million drop in compensation and related personnel expenses along with a $9.5 million reduction in program-specific expenses. The cost reduction initiatives we launched last year and that wrap up in midyear 2026 keep meaningfully lowering our expenses. Non-GAAP R&D declined by $25 million relative to the same period a year ago, which works out to a 32% reduction. Non-GAAP G&A fell by $10.1 million, or 44%, versus the prior year. Total non-GAAP expenses came in at $67.3 million, which is $35.1 million lower than the same period last year and reflects our new cost structure for 2026. We're holding to our cash runway guidance extending into the second half of 2028. By doing so, we'll be able to finance operations through key data milestones in the months ahead and keep backing our differentiated programs that could meaningfully improve patients' lives. On top of that, our cash position stands to gain from an approval milestone tied to the approval of VEPPANU, which we anticipate receiving later this year, plus the upfront and near-term milestones from our out-licensing agreement with Rigel. With that, I'll hand the call over to Randy for closing remarks. Randy?
During the last decade, Arvinas has established itself as a frontrunner in creating potent, selective, orally bioavailable, brain-penetrant PROTACs that have differentiated profiles. We have now effectively created the first PROTAC to secure FDA approval, something we think further confirms both our technology and our encouraging pipeline. By out-licensing VEPPANU to Rigel Pharmaceuticals, we can concentrate on our Phase 1 clinical programs, and every one of those moved forward because of highly differentiated preclinical data. Our belief is that these programs could reshape treatment paradigms in oncology and neurology; we are set up to provide several clinical updates throughout our portfolio, among them ARV-806 and ARV-393 later this year, and we expect to move our HPK1 degrader, ARV-6723, into the clinic over the next few months. Regarding ARV-102, we are working hard to supply the extra data required so that a Phase 1b trial can start in patients with PSP. We expect to launch that trial, and possibly a registrational trial, during the second half of the year. This year is a defining one for Arvinas; it brings focused execution, clinical momentum and several shots on goal, all supported by a strong balance sheet and a team that is deeply dedicated to pushing forward differentiated first-in-class therapies. We think the work underway could fundamentally alter treatment paradigms and produce meaningful impact for patients facing serious unmet needs. With that, I'll hand the call back to Jeff so we can start the Q&A. Jeff?
Appreciate that, Randy. Just a quick note for all of you — if you can't get into the queue, we're happy to handle your questions offline; that said, at this point I'll have the operator start the Q&A session. Operator?
This is Ana calling in for Kripa. I have just 2 fast questions regarding the Rigel partnership. Congratulations on getting that done. Would you be able to discuss a bit the economics tied to Rigel sublicensing the drug outside of the U.S., and how Arvinas and Pfizer might divide the percentage of the sublicensing revenue? And remind us what ongoing development activities Rigel is expected to contribute that $40 million towards?
Many thanks for the question. And yes, I simply want to begin by saying how delighted we are to have that finished, correct? So it has been truly important for us to ensure that VEPPANU reaches patients as rapidly as possible, now that it's approved as the first ever PROTAC degrader to get approved. We genuinely selected Rigel as a partner since we felt confident in their capacity to truly maximize the value of the drug and get it to patients quickly and efficiently. It has been a wonderful process with them and we are thankful to them for that; regarding the economics around it, maybe I'll hand it over to Andrew to discuss that.
Right. Thank you, Randy, and I appreciate that question. So, regarding how to view our out-licensing arrangement and the deal we've struck with Pfizer — both Pfizer and our company hold an equal 50-50 stake. That means whenever you see figures like milestone payments or royalty rates, you should picture Pfizer and us dividing those equally, straight down the center, across the whole term of the out-license, alright? The financial details we included in this morning's press release mostly relate to the U.S., since that's where our approval currently stands. Rigel holds rights worldwide. As you're probably aware, Rigel's primary concentration is on the U.S. market. So they'd have to secure partners in order to bring it to market abroad. A royalty would likewise flow back to Pfizer and to us, though we chose not to reveal that figure in the press release, given that right now we only have approval in the U.S.
Luke here, sitting in for Etzer. Regarding — regarding 806 and KRAS G12D, could you describe what the data scope will look like later in the year, in terms of patient numbers, how long follow-up runs, and so on? Also, what do you consider the bar for success when it comes to moving into future development? Then on 027, how well does the mouse model translate over to humans? And which biomarkers would be relevant for us to track from the healthy volunteer study? Or is that study truly just meant to assess safety?
Great. Appreciate the questions. Perhaps we can handle them one at a time, and I'll see if Noah and Angela want to chime in as well. Where 806 is concerned, those results are due to arrive during this year. As you're aware, we've been running a Phase 1 dose escalation since last year. That area, of course, has been moving quite quickly across the last few months, and it's one we're quite enthusiastic about, since we have a PROTAC degrader aimed at G12D. Our guidance has been that the data will land in 2026. We haven't gotten into the specifics of venue or timing. What we'll be presenting is safety, PK/PD, plus a few preliminary response rate figures. Naturally, the further into the year those results come out, the more durability information we expect to have — and that, clearly, is what we see as among the most critical pieces for any comparison. So that covers 806. Turning perhaps to 027, Angela, here's the question about how well the models translate.
Okay, regarding ARV-027, it targets the androgen receptor containing the polyglutamine repeat. In FDA-EMA, this represents the sole type of androgen receptor being expressed; it's what causes the disease at its root, and that's precisely our focus, correct? We possess extensive familiarity with degraders of the androgen receptor. Numerous ones have been advanced by us into clinical testing. And we understand that clinically, we are able to degrade the androgen receptor. Thus, what we aim to accomplish in patients is exactly that within muscle tissue, correct? This degrader of the androgen receptor was engineered by us to break down the polyglutamine repeat androgen receptor inside muscle. In that aggressive mouse model, we have demonstrated not just quite favorable dose-dependent breakdown of the polyglutamine repeat androgen receptor within muscle, but also that we have rescued two endophenotypes crucial to this disease: endurance along with strength, correct? Consequently, our aim is to eventually convert that into benefit for the disease. Yet initially, we must demonstrate through pharmacodynamics that we affect the target within muscle, and that is what we seek to do in the Phase 1 study involving healthy volunteers.
Caroline here, filling in for Yigal. Could you share what typical LRRK2 levels look like among those with PSP? And might the 50% knockdown observed in Parkinson's suffice to return PSP patients to a normal physiologic range?
Correct, that's precisely what we're thinking. Yet when it comes to Parkinson's patients and other neurodegenerative conditions in which LRRK2 has a part, the level is usually twice as high. That's the reasoning behind it. Noah, is there anything more you want to say?
Yes, we can discuss the values our assay is showing. It's worth keeping in mind that LRRK2 is a field that keeps changing, and various people involved in clinical trials, as well as those conducting general Phase 0 work measuring CSF, use different methods. Still, we know that healthy volunteers — roughly speaking, healthy volunteers have a median LRRK2 level slightly under 10 picograms per ml, while Parkinson's disease patients show around double that amount. And like you mentioned, I believe you described it exactly right. What we aim to do is bring Parkinson's disease patient levels down closer to what is observed in healthy comparators.
And what's encouraging is that this matches precisely what our research has demonstrated so far, correct? Therefore, in the trials we presented at AD/PD during our Phase 1, when healthy volunteers are compared against patients who have PD, we actually do observe that those patients possess roughly two times the amount of LRRK2. Plus, we can demonstrate that following administration of ARB-102, we subsequently lower and bring down that LRRK2 level by no less than 50%, which varies based on the dose achieved. Thus, we believe we definitely have a route to reach that point.
Also, building on that point, we have knowledge from published findings that, in postmortem brain, microglia are elevated twofold within the brain; and through normalizing that, our belief is that we will likewise normalize neuroinflammation along with the biomarkers that Noah and his team have demonstrated. We move — our hope is that this will change how the disease progresses.
From an unnamed analyst: Thanks; I just want to confirm something — when it comes to PSP patients, are you anticipating the same thing as with the Parkinson's patients?
Sorry, could you repeat that and restate the question?
It sounds like your answer was about Parkinson's patients, so I just wanted to confirm: you're expecting that same 50% knockdown in PSP patients as well.
Correct. So our expectation is the same there — well, we have shared — well, data published by other groups show a link between LRRK2 and PSP; our understanding is that, broadly speaking, across these neurodegenerative diseases, when the LRRK2 protein carries a mutation, and likewise when it is expressed at elevated levels, the result is endolysosomal dysfunction, which can promote buildup of pathological proteins. PSP is a perfect fit for that. It has the genetic association with LRRK2. Pathological tau accumulates. And what we expect is that LRRK2 reductions will be observed in the PSP patients, which would result in improvement in tau deposition, or a decrease in it.
Also, building on Noah's remarks, we see higher levels of LRRK2 and peripheral monocytes, meaning the biomarkers are up. LRRK2 is thus increased in PSP, and within a single year this tracks with faster clinical progression in a disease that is already progressing; that tells us lowering LRRK2 might actually change outcomes in that condition. That's PSP.
Congratulations on getting VEEPANU approved and on the Rigel transaction. My first question concerns the vepdeg program. When it comes to upcoming clinical trials or studies already underway, what structure will be used for managing them among you, Rigel, and Pfizer? Second, I'd like to know whether any combos exist involving ARV-806, the KRAS G12D degrader — are there possible pairing approaches as you examine the various solid tumor indications you're pursuing?
Sure. Appreciate those questions. Regarding VEEPANU, the studies currently running, as you're aware, are conducted by Pfizer and us. As we mentioned this morning in the releases, Rigel is going to supply certain cost offsets covering some of those existing development plans. When it comes to development work going forward, Rigel would then take on the economics; nonetheless, it makes sense to hold off a bit until we've made it through the relevant reviews and gotten that transaction completely closed prior to discussing it; and truly, development questions will be directed to Rigel. We're quite enthusiastic about where things stand at present regarding what we've built as a development plan for VEEP and delivering it to patients; as for 806 combos, Noah, would you like to chime in?
Alright. So we've provided certain figures before, and we'll keep providing them regarding 806 combinations — you can check forthcoming congresses to observe what occurs, say, when it's paired with chemotherapy; clearly, we're conducting internal efforts examining additional combinations. At this point, what we're guiding toward is just disclosing what our dose escalation yields. And...
Also, to mention as well, we're aware that from a degrader standpoint we can be combined with anti-PD-1; we've discussed this before and it appears distinct from daraxonrasib; in addition, we have demonstrated at a functional level that T-cell receptor function is not inhibited by us, unlike daraxon. So we believe there are opportunities for us in that area too.
Perhaps a question regarding the BCL6 effort. Might you share thoughts on how it could stand apart from what Bristol Myers Squibb has in development? Also, please clarify the design of your Phase 1 trial, the one testing the agent alone. Does it enroll any patient regardless of characteristics? Or is there some form of selection applied? And what efficacy threshold ought we to have in mind for B and T-cell lymphomas?
Sure. I appreciate that, Michael. All right, then — ARV-393, the BCL6 degrader we are developing, sits within our Phase 1 dose escalation at present. When this effort got underway, it was genuinely viewed as undruggable. Thus it has been encouraging to observe a portion of those initial results from BMS concerning response rates among B-cell tumors. And as we pointed out to everyone earlier today, even though that Phase 1 continues for us, we noted back in the fall that certain early responses have appeared in both the B and T-cell lymphomas. Regarding how it might be differentiated, Noah, would you care to comment?
Of course. I simply want to make something clear, though. You were asking what sets us apart from — the term you used was the CELMoD. Would it be helpful if we...
<<inaudible>>, that's right.
My understanding is that <<inaudible>>, or else BCL6 would be the one. I simply wanted to make sure that came across clearly in what I said.
The BCL6, I apologize.
The BCL6. All right. So the BCL6 degrader that has been published on shows activity in follicular and large B-cell lymphomas; so clearly we're examining that, and one way we've set our dose escalation study apart is that we've also zeroed in on AITL. This population — angioimmunoblastic T-cell lymphoma — accounts for roughly 3% of all NHLs. There's enormous unmet medical need, since following first-line shock, when patients tend to progress quite rapidly, on average within about a year or less, there genuinely isn't a solid standard of care. And we've noted that we've enrolled these patients into our study; we've observed responses. It becomes a key differentiating area when it comes to the development plan for us. You — regarding efficacy bars, so a distinction emerges between efficacy bars in T-cell malignancies and B-cell malignancies. I explained AITL to you. If we move over to B-cell malignancies and examine the 2 major ones, follicular, there's decreasing unmet medical need, because patients experience very long progression-free survivals with current first, second and third-line therapies. In large B-cell lymphoma, which we've alluded to or perhaps not even, I suppose, we've said that it's an area of greater interest to us, there's likewise decreasing medical need, yet still a substantial enough one, in second and third line, where despite having drugs such as CAR T that can be curative and having tremendous responses with bispecifics, fundamentally patients are still progressing. And we picture a future in which we'll be combining with bispecifics and impacting large B-cell lymphoma; so we already disclosed today that we began dosing patients in a large B-cell lymphoma dose escalation where we combine with glofitamab. So that becomes a significant part of our program.
Two things I'd like to ask about — one regarding KRAS, and another about the LRRK2 degraders. Let's begin with KRAS. At AACR 2026, there was fairly solid disclosure reach data showing what the competitive picture for KRAS inhibitors, and degraders of that kind, appears like. So what I want to know is: what did we learn from those AACR data reads concerning tolerability, efficacy, the efficacy bar, and the resistance side of the KRAS challenge?
Appreciate the question. Yes. Well, regarding KRAS broadly, and I'll hand things over to Noah shortly, I believe you're completely correct in highlighting that this space is changing fast. It's encouraging for us to see the RevMed data released, both about a month back and then in the newer publication, which sheds light on even some of the varying tiers of data and efficacy observed across different populations. So this is definitely an area we're monitoring closely, both as we advance the programs and as we prepare our own disclosures of data. That applies, I'd say, to our G12D program, currently in the clinic, and to our pan-KRAS program, which remains preclinical. As with other firms, we believe having several assets here will prove quite useful — the more targeted mutant degrader along with the pan. Noah, go ahead and weigh in on this area.
Appreciate that, Randy. So yes, there have certainly been significant takeaways, both from scientific meetings and clearly from what RevMed has announced. This is a field undergoing vigorous development—intense development—given what it could mean for patients. I believe we all see the transformative character of that first pan-RAS inhibitor, at least based on what has been shown regarding its effect as monotherapy in second-line PDAC. What we also see is that alongside that enormous efficacy—doubling overall survival—come toxicity burdens, correct? So it's a remarkable drug, yet patients are also dealing with substantial toxicity, and perhaps that stems from broad targeting that goes past KRAS to NRAS and HRAS as well. That creates an opening for those pursuing more targeted approaches, whether that involves G12D—which accounts for roughly 40% of that PDAC patient population, plus around 10% to 15% in CRC and a few percent in non-small cell lung cancer—or a pan-KRAS approach. That's precisely why we've decided to discover and develop drugs along these lines. Beyond that, there's a chance to stand apart through greater targeting specificity, but also, if you're able to lower the toxicity observed—especially the skin tox seen with pan-RAS—that likewise opens the door to broader combinability. So we see there may be chances to pair a pan-KRAS or a G12D targeting agent with minimal skin toxicity alongside EGFR receptors, which can push you toward CRC. And there are possible opportunities to combine with chemotherapy and employ higher doses than a pan-RAS could support. So we see that; we see how fierce the competition is in the G12D space. That's why we're simply keeping our heads down, charging forward, and eager to share data later this year from our G12D program.
Excellent. Perhaps, should there be enough time, might I pose a single inquiry regarding the LRRK2 program?
Go ahead.
Based on the information you presented at AD/PD, it would be quite interesting — and quite important — to understand what considerations led to the choice of focusing on the PSP trial. Was it a mechanistic rationale, a biomarker rationale, or an indication rationale that could potentially enable a quicker registrational study? So I just wanted to get a sense of the thinking — the strategic thinking — behind that decision.
Yes, absolutely. I'll hand it over to Noah regarding the design and the rationale for PSP as an indication. Regarding those AD/PD data, just to restate that point, and we did discuss it during the prepared remarks; but I genuinely believe that what we are doing in that space is fairly unique, correct? What we have managed to demonstrate there, in terms of both LRRK2 reduction and the downstream disease-relevant biomarkers, we believe truly sets itself apart from what other groups have demonstrated both preclinically and in the clinic, correct? So we are engaging downstream biomarkers that we know matter for neuroinflammation and for driving the disease, in a manner that we believe requires a degrader to access all of the functions of LRRK2, which could in the end be relevant in PSP as well as other diseases; but regarding PSP specifically, please, Noah?
Appreciate the question, and thank you, Randy. I believe that every factor you brought up, along with all the broad domains—indication, mechanism, biomarkers, everything—reinforces why PSP deserves this focus. Let me state plainly: there is no pivot taking place here. Our Parkinson's disease study happened because those patients can be enrolled without difficulty, because that condition interests us, and because we saw a long-term chance to develop this drug in that space too. The reason we picked it first, though, was that following a healthy volunteer study, it represented the most informative next step for confirming certain biomarker points relevant to PSP. Planning for the PSP program has therefore been underway for a long time. This illness carries tremendous unmet medical need, progresses quickly, and lets you pinpoint a more uniform group of patients experiencing fast progression, with meaningful year-over-year shifts on the PSP rating scale—meaning a trial can be conducted with a smaller number of patients while still detecting your drug's effect. From an indication standpoint, then: greater unmet need, reduced competition, a more uniform population, and a substantial indication in its own right, since as we've noted, it is a rare disease. Even so, 30,000 patients live in the U.S. Similar figures can be estimated for Europe, clearly, and for Asia. That covers the indication aspect. On mechanism, the underlying problem is identical. Endolysosomal dysfunction is present, along with degeneration of synapses and circuits in the brain that drive the disease. In this specific illness, what you find is tau pathology instead of something such as alpha-synuclein, where I'd say heterogeneity is greater and the community has less certainty regarding how it operates to propel disease. There is a shared understanding that 4R tau serves as a driver of PSP. So that's another thing we will be able to measure. Turning to biomarkers, we have already completed the groundwork in PD, and it carries over; thus we know the drug degrades LRRK2 in the brain in a manner that can be predicted. We know we can produce reductions in biomarkers tied to that, and to the lysosomal dysfunction I mentioned before, which propels 4R tau buildup. That is what let us select a dose range to advance into our Phase 1b and our registrational Phase 2 program.
Congratulations on everything you've accomplished so far. I'd also like to zero in on the RAS programs. You're now entering the expansion cohorts — the Phase 2 expansion cohorts. For the G12D, it looks like the focus is specifically pancreatic. I was wondering what prompted that choice. Of course, PDAC is probably the most crowded of the KRAS-related areas, and I'm sure you're aware the landscape there is shifting quickly. So what pushed you toward PDAC in particular? Have you thought about running expansion cohorts in other indications where RAS matters? And when might we learn more about some of those combination strategies you brought up in earlier responses? Then, on the pan-KRAS front, I was quite interested to hear about and see the recent publication on the enhanced synergy with the anti-PD-1. I was wondering what your thinking is on the mechanism behind that — why a pan-KRAS, or a degrader, would show stronger synergy with PD-1 compared to pan-RAS agents.
Jon, thanks for asking. We'll handle this in 3 parts. I'll begin, then hand it to Noah for PDAC, and then Angela is probably best positioned to address the pan and the PD-1; and look, I think it's worth saying again, right? As this space develops, we're obviously watching what's shifting. What hasn't shifted is our preclinical data, right? What we saw in our preclinical work gave us grounds to think—judging by the results we had—that we might achieve greater potency at suppressing tumor growth than the inhibitors and degraders that are already in the clinic. That's the basis for our belief that we could do better. And doing better might translate into durability, keeping resistance from developing. On top of that, as Noah said before, there are possibilities involving how well it combines with other agents and how tolerable it is. So my sense is we'll be examining each of those areas. One more point I want to make prior to handing things over to Noah regarding pancreatic: whenever a program emerges such as the one RevMed has, one that's set to transform the field, success won't hinge solely on winning direct comparisons. As the entire treatment approach evolves over the coming years, fresh possibilities will open up within that area. That said, Noah, perhaps you can speak to PDAC and combinations, and Angela on pan.
Absolutely, and thanks for that, Jon. So, picking up on what Randy mentioned regarding potency—something we observed in preclinical work—now that we've had a chance to review findings from other companies operating in this area, it's clear that potency might end up being quite significant. We're aware that the degrader from Astellas couldn't reach the maximum dose they'd originally planned, due to DLTs during their Phase 1 trial. And with daraxonrasib, when it was paired with Gem-Abraxane in the first-line PDAC study, a dose reduction became necessary, correct? Signals like these indicate that a more potent drug could potentially hit the needed target engagement while sidestepping certain toxicities that build up when very high doses are required. That said, we're taking a sensible approach. Dose escalation has been completed. For project optimist, you have to select a recommended Phase 2 or Phase 3 dose—whichever way you prefer to frame it—and that calls for some expansion. When you carry that out—and PDAC is the most logical choice since it's a monotherapy setting. Patients can be enrolled. The unmet need exists, and I believe the speed of our trial so far has confirmed that. We—I don't want to—those are the steps we've laid out. So I won't go past that into discussing other combinations or other indications. Right now, the priority is figuring out the optimal monotherapy dose. After that, we could have a conversation. Once we've shared that, we can discuss where else we might go. I'll hand it over to Angela for the KRAS part.
Absolutely. Appreciate that, Jon. And thank you for pointing out our oral pan-KRAS poster presented at AACR. What we demonstrated is that we had a differential effect compared with daraxon when it comes to the tumor microenvironment — daraxon, as we observed, was suppressing T-cell function according to 3 distinct functional measurements. However, within the T-cell microenvironment, we're aware that we aren't just bringing in T-cells; we're also drawing additional cells into the tumor. As a result, we're observing more complete responses, which stems from that change taking place in the microenvironment. We also demonstrated that we were inducing MHC. That means we're inducing the tumor's antigenicity, so stay tuned, since more mechanistic details about what is happening in the tumor microenvironment are coming. This is an exciting moment for the degrader.
Angela, I just want to make sure I've got this right. From what you said, it sounds like you're describing an effect that works across KRAS, where keeping some of daraxon's wider activity intact could matter more than any degrader mechanism. What I'm wondering is whether, at this stage, there's any way to separate those two things out.
Let me make sure I follow the question and respond clearly. Yes, that's right. Our view is that by way of degradation — whether that's through G12D with 806 or through a pan-KRAS mechanism — the degrader behaves differently from the KRAS (ON) inhibitor within the tumor microenvironment. That is precisely what our mechanistic study demonstrated. When we looked at the tumors themselves, we saw that we are in fact drawing in a stronger T-cell signal, and we also observed that we are raising the antigenicity of the tumor, bringing more immune cells into the environment — into the tumor microenvironment — and we are seeing more complete responses. Beyond that, we demonstrated how our molecule's impact differs in a dose response — our degrader in a dose response — compared with the KRAS (ON) clinical inhibitor across 3 different T-cell functional assays; meaning we are not suppressing T-cell function, while daraxon does.
Congratulations on everything you've achieved so far. For a second, I'd like to go back to 027, the program in spinal and bulbar Kennedy's disease. I'm wondering whether you might give us some background on how it stacks up against 766 for prostate cancer, given that both of them break down androgen receptors, and also on its potency and what magnitude of effect you believe would be needed to deliver a clinically meaningful benefit? That's my first one; my second one concerns VEPPANU and where things stand or what's planned for filings in Europe and elsewhere around the world, and how we ought to think about modeling that going forward now that it's partnered with Rigel.
Great. Thanks. Regarding 027 for SBMA, that program kicked off earlier this year; and you're correct to bring up the luxdegalutamide deal we struck with Novartis a few years back for prostate cancer. What mainly separates the molecules is that although both break down AR, 027 was picked specifically because it can degrade AR within muscle. So it penetrates muscle effectively, which matters a great deal since that's where we want activity for the neuromuscular condition of SBMA, unlike 766 or luxdegalutamide, the one tied to prostate cancer with Novartis; as for depth and moving ahead, clearly, we hold the U.S. approval. Additional regulatory efforts will fall to Rigel, the new partner. Of course, there's an ASR period we need to get past. Once that's done, it likely makes sense to reach out to Rigel about any questions on future development. We're definitely thrilled for them to assume responsibility for both commercialization and any additional development of that.
This is Jacob, filling in for Derek. I just want to get something straight — did you mention that ARV-102 is paused here in the U.S. while it continues outside the U.S.?
In essence, that is — yeah, you've got it right. So regarding 102, as Noah mentioned, once that IND gets filed, we enter the 30-day window in which the FDA basically has 2 choices: either allow it to proceed or place it on hold. So although that study hasn't started yet here in the U.S., and no patients have been dosed by us in the U.S., technically, yes, it is on hold. The studies that have been running outside the U.S. aren't impacted. And the plan is that going forward, as we talk with both the FDA and ex U.S. regulatory authorities, we'll look at pursuing both paths in parallel.
Got it. So what's holding things up when it comes to launching in the U.S. compared with outside the U.S.?
Noah, why don't you handle that?
Right, Randy. Basically, 2 years back, prior to launching this program, we sat down with the FDA, and we laid out — or rather, we inquired about — what it would take to get started in the U.S. At that point, we'd already made a strategic call to conduct the healthy volunteer work and ultimately carry out the Parkinson's disease study in Europe so the program could get underway, which is very typical in neuro drug development. They had spelled out for us that when it comes to chronic treatment, the following information needs to be supplied. We supplied that information, and at this point they were requesting additional items beyond what had initially been asked for. So we need to get it squared away; we'll pass it along to them, but the discussion is going to keep going.
Turning back to PSP as an indication, could you remind us how these patients get diagnosed and where they are usually treated? Are they mostly gathered at particular centers of excellence? And do you have any thoughts yet on what a possible pivotal study might look like regarding its duration and primary endpoints?
Jeet, thanks for asking. Noah, go ahead.
Okay, yes, thank you, Jeet. So generally, these individuals get their diagnosis only after being incorrectly told they have Parkinson's disease, correct? The reason is that a person arrives showing tremor, stiffness, and instability — those are typical ways Parkinson's disease shows up, and they also appear in PSP. There's a sort of clinical feature that sets them apart, namely a vertical gaze issue resulting in falls. And another clinical management clue pushes you toward PSP: those with Parkinson's disease get prescribed some form of L-dopa, and usually they'll demonstrate a degree of improvement. Yet in the case of a PSP patient, that treatment does nothing for them. So picture it as an initial situation of frequent misdiagnosis, unless falls show up at presentation, in which case things become clearer. After that, they receive this diagnosis. And sadly, this illness advances quickly, and that's how it differs from Parkinson's disease. As mentioned, the span from diagnosis until death runs about 5 to 7 years. So that is — now you asked about where these patients receive treatment. Certainly some centers of excellence exist, yet this is something observed widely — most — every neurologist will encounter PSP patients eventually. Certain centers treat a substantial number of them. There's a background of conducting clinical trials at multiple centers across the U.S. At present, the sole other Phase 3 program that appears likely to run alongside this one is the study from Novartis, since they've disclosed an ASO aimed at tau that's advancing into Phase 3, and it entails injections given quarterly, intrathecal injections of an ASO. We think we can enroll our patients effectively, given the lengthy history of worldwide recruitment for PSP trials; plus we suspect there might even be a leaning toward the kind of study we're conducting. Regarding endpoints and being aware of that study's size, we've previously stated in general terms that it's a few hundred patients; it will be 2 dose of — presumably 2 dose levels against placebo and call for a year of treatment.
This is Nick, filling in for Tyler. Going back to the LRRK2 program. Even though you're putting PSP first for the reasons you listed earlier, is there anything you might see in your PSP data down the road that would change your mind about advancing in Parkinson's disease? Or might the Phase 2 data for Denali's LRRK2 inhibitor later this year help support moving into Parkinson's disease?
I guess the quick answer is no, in the sense that I wouldn't expect — we believe the data we've produced so far, in both healthy volunteers and patients with Parkinson's, can carry over to both patients with Parkinson's and PSP. So from that angle, there's definitely things we could do in PSP and data we could see that would give us greater confidence in our ability to do what we've already begun to demonstrate, which is making 102 an orally available brain penetrant drug that lowers LRRK2 exactly where we wanted to degrade it, in deep brain regions. As for the Biogen readout, that's certainly something we're watching. Just to remind everyone, we're discussing 102 as a degrader here, targeting all 3 aspects of LRRK2's function, which we believe matters for the reasons we've already laid out on this call. And because of that, we're certainly hopeful the trial is positive for patients; and we think that if it is, we can show a benefit beyond that with the technology we have. And if it isn't, we think the differentiation we've already demonstrated both in the clinic with biomarkers and preclinically with things like endolysosomal function, the ability to reduce tau, we think there's plenty of data we've already shared showing how different we are from that program. So we'll be moving ahead.
This is Manoj calling in for Akash. We have a single question regarding ARV-806. It appears that in the Phase 2 study of ARV-806, you plan to randomize 2 dose levels, instead of picking just one dose from the escalation stage. I am simply trying to grasp the reasoning behind randomizing those 2 dose levels into Phase 2, and which endpoints will ultimately determine the final dose choice — for example, ORR or KRAS degradation <<inaudible>> — I am just trying to follow the logic behind that.
Yes, that is correct. As we move into dose expansion, our plan is to evaluate 2 doses, which I believe is pretty standard in oncology. Noah, is there anything you would like to add regarding that?
Yeah. Every one of those considerations will play a role there, which means whenever you run a dose expansion and you're working to optimize that dose, you need to convince yourself you've landed on the correct dose, and honestly, you also need to convince the FDA. That matters a great deal to them. You factor in all of these things; we're going to examine the overall response. We're going to examine whatever degradation data we can gather. You're evaluating safety along with other measures of efficacy. So everything feeds into that. Still, my sense is that what we have here is a fairly standard expansion.
Daniel Bronder here, filling in for Li. Looking ahead, what's your take on the patient population for the KRAS program? I saw that on clinicaltrials.gov, for the KRAS G12D degrader, you've excluded any prior treatment with KRAS-targeted agents so far. Do you expect to develop it in that same phase? Will you be pursuing pan-RAS or pan-KRAS, or even targeted KRAS G12D drugs down the road?
Yeah. You're basically pointing right at the answer, which is there are many options available. The first priority is demonstrating our drug works, correct? In Phase 1, we need to prove we can be competitive, and that's our aim with both the escalation and the expansion. Past that, as your question and others have hinted, there are opportunities across different indications. There are opportunities for monotherapy versus combination. You brought up KRAS pretreatment as other programs reach the market and get adopted. That will definitely open up a fresh opportunity to pursue that alongside other therapies, and we'll need to determine how to compete in that area. One thing I've said consistently since becoming CEO a few months ago is that we have no interest in generating incremental — I mean 2 kinds of programs. So it matters for us, particularly as a company with 4 programs in Phase 1 currently, and a fifth starting in the second half of the year. It's truly important that we concentrate Arvinas on where we can play to win and where we can stand apart; and we must demonstrate that we can. As we build that development plan, we'll proceed if we can. So again, it comes back to this: we look forward to sharing those data this year, and that will be the moment to say a bit more about development plans past the initial stages of monotherapy expansion and escalation.
Okay, thanks so much, everyone, for being here. I doubt I could express this often enough, but my pride in this team and in where we stand is immense. Within just the last few — over the last 10 days, 11 days, we received approval for BEP, which is the first heterobifunctional degrader PROTAC ever to reach the market. Like I mentioned before, only a very small number of companies manage to guide a program — guide a technology from its very beginning all the way to a first approval. That makes me incredibly proud. Collaborating with Pfizer to have the VEPPANU program licensed to Rigel so they could launch it is also a massive achievement; and just as I said a moment ago, we have 4 programs in the clinic. We already shared data for one of them this year, with a couple more to come alongside some trial starts; so there's plenty ahead, and we're eager to keep you informed as things progress.
We appreciate everyone joining us on this call today. That brings the program to an end. You're welcome to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Arvinas, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Arvinas, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.